A RETROSPECTIVE ANALYSIS OF NITRIC-OXIDE INHALATION IN PATIENTS WITH SEVERE ACUTE LUNG INJURY IN SWEDEN AND NORWAY 1991-1994

Citation
O. Luhr et al., A RETROSPECTIVE ANALYSIS OF NITRIC-OXIDE INHALATION IN PATIENTS WITH SEVERE ACUTE LUNG INJURY IN SWEDEN AND NORWAY 1991-1994, Acta anaesthesiologica Scandinavica, 41(10), 1997, pp. 1238-1246
Citations number
32
Categorie Soggetti
Anesthesiology
ISSN journal
00015172
Volume
41
Issue
10
Year of publication
1997
Pages
1238 - 1246
Database
ISI
SICI code
0001-5172(1997)41:10<1238:ARAONI>2.0.ZU;2-A
Abstract
Background: Patients with severe acute lung injury (ALI) have been tre ated compassionately on doctors' initiative with inhaled nitric oxide (INO) in Sweden and Norway since 1991. In 1994 the previously used tec hnical grade nitric oxide was replaced by medical grade nitric oxide. Methods: We have carried out a retrospective data collection on all id entified adult patients treated with INO for > 4 h during the period 1 991-1994 focusing on safety aspects and patient outcome. We used the f ollowing exclusion criteria (1) Age < 18 years, (2) Simultaneous treat ment with extracorporeal removal of CO2 (3) NO inhalation period < 4 h , (4) Incomplete or missing patient harts, (5) Use of INO in order to treat pulmonary hypertension following cardiac surgery, with little or no acute lung injury. Results: Inclusion criteria were met by 56 out of 73 identified patients. Mean age was 48 +/- 19 years and the median duration of mio treatment was 102 h. PaO2/FIO2 ratio at start of trea tment was 85 +/- 33 mm Hg with a lung injury score (LIS) of 3.2 +/- 0. 8. The aetiology of the lung injury was pneumonia (n = 27), sepsis (n = 12) and trauma (n = 8). Survival to hospital discharge was 41% and s urvival after 180 d was 38%. Three serious adverse events were identif ied, two from technical failures of the INO delivery device and one wi thdrawal reaction necessitating slow weaning from INO. No methaemoglob in values > 5% were reported during treatment. Conclusion: The overall mortality did not differ dramatically from historical controls with h igh mortality. Only a randomised study may determine whether INO as an adjunct to treatment alters the outcome In severe ALI. One cannot at present advocate the routine use of INO in patients with ALI outside s uch studies.